science
AbbVie to Acquire Apogee Therapeutics for $10.9 Billion in Cash
@statnews reported that AbbVie will buy Apogee Therapeutics, an immunology drug developer, for $10.9 billion. The deal values Apogee shares at $135.11, a 50 percent premium to the prior close. Apogee's lead candidate targets IL-13 for atopic dermatitis and asthma.
Audio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
AbbVie announced on June 22, 2026, that it will acquire Apogee Therapeutics for $10.9 billion in cash. The transaction values Apogee at $135.11 per share, a roughly 50 percent premium to its previous closing price. @statnews reported that Apogee develops immunology drugs.
Its lead candidate, zumilokibart, targets the inflammatory cytokine IL-13 and is being tested in atopic dermatitis as well as in combination with another experimental medicine for asthma. The drug could be administered to patients two to four times per year after initial treatment.
The acquisition continues a pattern of larger pharmaceutical companies purchasing smaller biotechs, @statnews reported.
Apogee's focus on immunology aligns with AbbVie's established presence in the field. The Financial Times reported last week that the deal was under discussion.
Transparency
1 source · single source
CorroborationModerate · 1 source
